CLARUS THERAPEUTICS HOLDINGS (CRXT) Stock Income Statement
NASDAQ:CRXT - Nasdaq - US18271L1070 - Common Stock - Currency: USD
| TTM (2022-6-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|
| Revenue | 16.91M | 13.96M | 6.37M | 0.00 | |||
| Cost Of Goods | 3.62M | 2.72M | 8.69M | 0.00 | |||
| Gross Profit | 13.29M | 11.24M | -2.32M | 0.00 | |||
| Operating Expenses | 53.19M | 50.97M | 44.86M | 17.88M | |||
| Research and Development | 3.92M | 3.63M | 3.41M | 3.09M | |||
| Selling, General, and Administrative Expenses | 49.27M | 47.34M | 41.45M | 14.79M | |||
| Operating Income | -39.90M | -39.73M | -47.18M | -17.88M | |||
| Interest Income/Expense | -10.36M | -15.89M | -15.37M | -23.79M | |||
| Other Income/Expense | 13.88M | 12.51M | 66.89M | 13.00K | |||
| Non Recurring Items | N/A | 2.50M | N/A | N/A | |||
| Income Before Taxes | -32.63M | -40.62M | 4.34M | -41.65M | |||
| Income Tax | N/A | 0.00 | 0.00 | 0.00 | |||
| Net Income | -32.63M | -40.62M | 4.34M | -41.65M | |||
| EBITDA | N/A | -39.71M | -47.16M | -17.87M | |||
| Per Share Data | |||||||
| EPS Diluted Total Ops | -1.12 | -1.69 | 0.20 | -1.92 | |||
| Non GAAP EPS | -1.27 | N/A | N/A | N/A | |||
| Statistics | |||||||
| Gross Profit Margin | 78.57% | 80.51% | -36.40% | N/A | |||
| Profit Margin | -193.00% | -291.02% | 68.22% | N/A | |||
| Operating Profit Margin | -235.99% | -284.67% | -740.73% | N/A | |||
All data in USD